Boothbay Fund Management LLC Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Boothbay Fund Management LLC boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 147.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,148 shares of the company's stock after acquiring an additional 49,485 shares during the period. Boothbay Fund Management LLC owned 0.15% of Structure Therapeutics worth $2,255,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GPCR. Capital International Investors lifted its holdings in shares of Structure Therapeutics by 6.8% during the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company's stock valued at $43,909,000 after purchasing an additional 103,059 shares during the last quarter. Rock Springs Capital Management LP increased its position in Structure Therapeutics by 1.6% during the 4th quarter. Rock Springs Capital Management LP now owns 1,080,963 shares of the company's stock valued at $29,316,000 after buying an additional 17,053 shares in the last quarter. Principal Financial Group Inc. raised its stake in Structure Therapeutics by 45.1% during the fourth quarter. Principal Financial Group Inc. now owns 791,134 shares of the company's stock valued at $21,456,000 after buying an additional 245,775 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Structure Therapeutics by 4.5% in the fourth quarter. Franklin Resources Inc. now owns 738,090 shares of the company's stock worth $20,017,000 after acquiring an additional 31,984 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Structure Therapeutics by 12.3% in the fourth quarter. American Century Companies Inc. now owns 612,616 shares of the company's stock worth $16,614,000 after acquiring an additional 67,325 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on GPCR shares. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target on the stock. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Stock Up 1.2 %

GPCR stock traded up $0.33 during trading on Thursday, hitting $27.33. The company had a trading volume of 657,602 shares, compared to its average volume of 919,231. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74. The company has a 50 day simple moving average of $20.28 and a 200-day simple moving average of $27.59. The firm has a market capitalization of $1.57 billion, a P/E ratio of -36.93 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.